POS0571 NON-OBESE RHEUMATOID ARTHRITIS PATIENTS WITH LOW LOW-DENSITY LIPOPROTEIN HAVE GREATER CORONARY ATHEROSCLEROSIS BURDEN, PLAQUE PROGRESSION AND CARDIOVASCULAR EVENT RISK
Authors: G. Karpouzas, S. Ormseth, E. Hernandez, M. Budoff
Journal: Annals of the Rheumatic Diseases (2021)

Background: Rheumatoid arthritis (RA) patients with low body weight incur higher mortality than obese patients. Paradoxically, RA patients in the lowest low-density lipoprotein group (LDL &lt;70 mg/dl) may also experience higher cardiovascular disease (CVD) risk. Objectives: We here explored whether abdominal obesity (waist-to-height ratio &gt;0.58 in females and &gt;0.63 in males) might moderate the effect of low LDL (&lt;70mg/dl) on coronary atherosclerosis burden, progression and long-term CVD risk in RA. Methods: One hundred fifty patients without symptoms or diagnosis of CVD underwent coronary computed tomography angiography. Plaque progression was evaluated 6.9±0.3 years later in 101 patients. Coronary artery calcium, number of segments with plaque (segment involvement score), and extensive (&gt;4 segments with plaque) or obstructive disease (&gt;50% stenosis) were assessed. CVD events were prospectively recorded, including cardiac death, myocardial infarction, unstable angina, revascularization, stroke, claudication, and heart failure hospitalization over 6.0±2.4 years of follow-up. Lipoprotein classes were directly measured. Oxidized LDL (oxLDL) was assessed with monoclonal antibody E06. Adjusted robust linear regression evaluated interactions between abdominal obesity and LDL groups on plaque outcomes. Per segment, adjusted robust logistic regression models explored obesity x LDL group interactions on new plaque formation and stenotic progression of prevalent plaques. Robust Cox regression models stratified by abdominal obesity evaluated the effect of LDL group (&lt;70 vs. &gt;70 mg/dl) on CVD events. Results: Non-obese patients with low LDL had the highest plaque burden (Figure 1A, all p &lt; 0.02). Obesity moderated the effect of LDL on likelihood of extensive/obstructive disease ( P for interaction = 0.061); specifically, LDL&lt;70 associated with an increased likelihood of extensive/obstructive plaque in non-obese (adjusted OR 4.75 [95% CI 1.18-19.07], P = 0.028) but not obese patients (adjusted OR 1.55 [95% CI 0.39-6.08], P = 0.532). No differences in disease activity or inflammatory markers were seen across groups. Compared to LDL&gt;70 mg/dl, low LDL predicted an increased likelihood of high oxLDL (&gt;median) in non-obese patients (adjusted OR 5.10 [95% CI 1.46-17.75], P = 0.011) but not obese patients (adjusted OR 0.50 [95% CI 0.11-2.21], P = 0.36, Figure 1B). Obesity further moderated the effect of LDL on likelihood of future development of plaque ( P for interaction = 0.002) and increased stenotic severity of existing plaques ( P for interaction = 0.040); in non-obese patients, low LDL associated with a greater likelihood of new plaque forming in segments without baseline plaque (adjusted OR 4.68 [95% CI 2.26-9.66]) and worsening stenotic severity in segments with prevalent plaque (OR 5.35 [95% CI 1.62-17.67]). This was not observed in obese patients (Figure 1C). Notably, in non-obese patients, low LDL associated with higher CVD event risk compared to those with LDL&gt;70 mg/dl (HR 7.94 [95% CI 1.52-41.36], P = 0.015). This was not the case in obese patients (HR 0.32 [95% CI 0.04-2.40], P = 0.27, Figure 1D). Conclusion: In non-obese RA patients, LDL&lt;70 mg/dl may reflect higher LDL oxidation and was associated with higher baseline coronary atherosclerosis burden, new plaque formation, stenotic plaque progression and greater CVD risk than LDL&gt;70 mg/dl. Disclosure of Interests: George Karpouzas Speakers bureau: Sanofi/ Genzyme/ Regeneron, Consultant of: Sanofi/ Genzyme/ Regeneron, Grant/research support from: Pfizer, Sarah Ormseth: None declared, Elizabeth Hernandez: None declared, Matthew Budoff Consultant of: Pfizer